Swiss National Bank Acquires 29,100 Shares of Certara, Inc. $CERT

Key Points

• Swiss National Bank increased its stake in Certara, Inc. by 13.2% during the first quarter, bringing its total ownership to 249,500 shares valued at approximately $2.47 million.
• Institutional investors hold 73.96% of Certara's stock, with notable increases in holdings from firms like ArrowMark Colorado Holdings and Ameriprise Financial, which raised their positions by 164.2% and 864.0%, respectively.
• Certara's quarterly earnings report showed an EPS of $0.07, below expectations, but the company still recorded a 12.1% revenue increase to $104.57 million year-over-year.

Swiss National Bank lifted its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 13.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 249,500 shares of the company's stock after purchasing an additional 29,100 shares during the period. Swiss National Bank owned 0.15% of Certara worth $2,470,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the stock. Versant Capital Management Inc grew its position in shares of Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after buying an additional 1,866 shares during the last quarter. Wells Fargo & Company MN increased its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new position in Certara during the fourth quarter worth $47,000. Associated Banc Corp bought a new position in shares of Certara during the 1st quarter worth approximately $101,000. Finally, Portside Wealth Group LLC bought a new position in Certara during the first quarter worth $104,000. 73.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CERT has been the topic of several research reports. Morgan Stanley began coverage on shares of Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective on the stock. UBS Group dropped their price target on Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. KeyCorp lowered their target price on Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Finally, Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $15.14.

Certara Stock Up 0.7%

Shares of NASDAQ:CERT traded up $0.08 during mid-day trading on Wednesday, hitting $10.95. 493,426 shares of the company traded hands, compared to its average volume of 1,693,528. The stock has a 50-day moving average price of $10.81 and a two-hundred day moving average price of $11.53. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $15.69. The stock has a market cap of $1.76 billion, a P/E ratio of 218.94 and a beta of 1.42. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same quarter last year, the firm posted $0.07 earnings per share. The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. On average, equities research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.